New strategy to focus exclusively on BOW080 (eculizumab biosimilar) and BOW070 (tocilizumab biosimilar) in rare diseases with a combined target market opportunity of close to $6 billion of...
BOSTON, March 15, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a pure-play biosimilar company focused on the global development and commercialization of biosimilar...
BOSTON, March 01, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a pure-play biosimilar company focused on the development and commercialization of biosimilar...
UNIFORMi Study builds on prior successful Phase 1 and Phase 3 studiesIntended to support harmonized global filing for BOW015 in 2017BOW015 is a biosimilar for Remicade®, which had global...
BOSTON, Feb. 05, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal...
BOSTON, Feb. 03, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal...
Readiness for on-time initiation of pivotal global registration study with completion of manufacturing process lockBOW015 remains on track for 2017 global filingBOW015 targets large market...
BOSTON, Nov. 16, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar...
BOSTON, Nov. 11, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar...
BOSTON, Nov. 10, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 0 | 0 | CS |
26 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 0 | 0 | CS |
52 | -9.9E-5 | -99 | 0.0001 | 0.0001 | 1.0E-6 | 5933 | 1.25E-6 | CS |
156 | -0.005999 | -99.9833333333 | 0.006 | 0.006 | 1.0E-6 | 7768 | 0.00016341 | CS |
260 | -0.000999 | -99.9 | 0.001 | 0.24 | 1.0E-6 | 56994 | 0.00897282 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.